4-hydroxy-2-oxo-2,3 -dihydro-1,3-benzothiazol-7yl compounds for modulation of B2-adrenoreceptor activity

Details for Australian Patent Application No. 2007336075 (hide)

Owner AstraZeneca AB

Inventors Meghani, Premji; Connolly, Stephen; Humphries, Alexander

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2007336075

PCT Pub. Number WO2008/075026

Priority 60/910,045 04.04.07 US; 60/951,980 26.07.07 US; 60/870,922 20.12.06 US

Filing date 19 December 2007

Wipo publication date 26 June 2008

Acceptance publication date 27 October 2011

International Classifications

C07D 285/14 (2006.01) Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups

C07D 417/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

18 June 2009 PCT application entered the National Phase

  PCT publication WO2008/075026 Priority application(s): WO2008/075026

2 July 2009 Amendment Made

  The nature of the amendment is: Amend the invention title to read 4-hydroxy-2-oxo-2,3 -dihydro-1,3-benzothiazol-7yl compounds for modulation of B2-adrenoreceptor activity

27 October 2011 Application Accepted

  Published as AU-B-2007336075

23 February 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007336077-New combination for use in the treatment of inflammatory disorders

2007336074-Amine derivatives and their use in beta2-adrenoreceptor mediated diseases